Seyed Alireza Javadinia/LinkedIn
May 17, 2025, 08:55
Seyed Alireza Javadinia: MPA-Guided Chemotherapy Strategy in ER+/HER2- BC Presented at ESMO Breast 2025
Seyed Alireza Javadinia, Vice President for Research and Technology, Assistant Professor and Radiation Oncologist at Sabzevar University of Medical Sciences, shared a post on LinkedIn:
“New data from ESMO Breast 2025’s OPTIMA prelim study (Abstract 190O) support using a gene expression-based multiparameter assay (MPA, Oncotype DX) to guide chemotherapy decisions in ER+/HER2– breast cancer. In 387 patients, 10-year invasive breast cancer-free survival rates were comparable: 80% with standard chemotherapy plus endocrine therapy vs. 78% with MPA-directed therapy (HR 1.18, 95% CI 0.75–1.83).
These results validate MPA’s role in identifying low-risk patients (recurrence score ≤25) who may safely forgo chemotherapy, reducing overtreatment. Prof. Christos Sotiriou emphasizes that MPAs capture tumor proliferation and ER status, key to predicting chemotherapy response. Ongoing phase III OPTIMA results, expected in 2026, may further refine treatment strategies.”
More posts featuring Seyed Alireza Javadinia.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 8, 2025, 10:36
Jun 8, 2025, 10:14
Jun 8, 2025, 10:02
Jun 8, 2025, 09:53